$ 38.99Add to cart
Clopixol (Zuclopenthixolum, Zuclopenthixole, Klopiksol) - antipsychotic (neuroleptic), thioxanthene derivative.
Antipsychotic effect of neuroleptics is usually associated with the blockade of dopamine receptors that appear to cause a chain reaction in which the involved mediator systems and others.
Clopixol has a pronounced antipsychotic and specific inhibitory effect. Clopixol may cause a transient, dose-dependent sedation. The rapid development of sedation at the beginning of therapy (until the antipsychotic action) is advantageous in the treatment of acute and subacute psychoses. Tolerance to the unspecific sedative effect of the drug occurs rapidly. The specific inhibitory effect Clopixol particularly beneficial in the treatment of patients with agitation, anxiety, hostility or aggressiveness.
Zuclopenthixol bioavailability when administered orally is about 44%. The maximum serum concentration achieved after 4 h. Zuclopenthixol slightly crosses the placental barrier in small amounts excreted in breast milk. Metabolites not have neuroleptic activity and are excreted primarily in the feces and partially urine. The biological half-life of about 20 hours.
Acute poisoning with alcohol, barbiturates, opiates; coma.
Perhaps Clopixol impact on driving ability and other mechanisms. Therefore, at the beginning of therapy is necessary to exercise caution until no reaction will be determined for treatment of the patient.
When long-term therapy is necessary to carry out careful monitoring of patients. With extreme caution should be appointed Clopixol patients with convulsive disorders, chronic hepatitis and cardiovascular disease.
Clopixol not recommended during pregnancy and lactation.
Ladasten is taken orally with or without food.
Doses should be individualized according to the patient's condition. Typically, the original should be used in small doses, which are then rapidly built up to an optimum effective level depending on the clinical effect.
An acute attack of schizophrenia, other acute psychotic disorders; severe agitation and mania. Typically 10-50 mg / day.
When expressed disorders and conditions moderate initial dose of 20 mg / day can be increased if necessary to 10-20 mg every 2-3 days up to 75 mg per day or more.
Chronic psychotic states of schizophrenia and other chronic psychoses. The maintenance dose of 20-40 mg / day.
Agitation in patients with mental retardation. Typically, 6-20 mg / day. If necessary, the dose may be increased to 25-40 mg / day.
Agitation and confusion in patients with senile disorders patients. Typically 2-6 mg / day (preferably in the evening to give) can be increased to 10-20 mg / day as needed.
From the nervous system. Perhaps the development of extrapyramidal symptoms, especially at the initial stage of treatment. In most cases, they are corrected dose reduction and / or the purpose of anti-Parkinsonian drugs. However, the last regular prophylactic use is not recommended. In rare cases, long-term therapy in patients may develop tardive dyskinesia. Anti-Parkinsonian drugs do not eliminate its symptoms. Recommended dosage reduction or, if possible, discontinuation of therapy.
On the part of mental activity. Sleepiness at the initial stage.
Since the autonomic nervous system and cardiovascular system. Dry mouth, disturbance of accommodation, urinary retention, constipation, tachycardia, orthostatic hypotension and dizziness.
On the part of the liver. Rarely observed minor transient changes in liver function tests.
Chemically incompatible combination has been established. Clopixol may enhance the sedative effects of alcohol, barbiturates and other central nervous system inhibitors. Clopixol should not be given together with guanethidine and similarly acting means, as neuroleptics may block their antihypertensive effect. Klopiksol may decrease the effectiveness of levodopa and other adrenergic agents, and the combination with metoclopramide and piperazine increases the risk of extrapyramidal symptoms.
Important notice- the outer box design may vary before prior notice!